阿德福韦酯联合国产重组人干扰素α-2b对慢性乙肝患者抗病毒疗效的对比分析  

Efficacy of adefovir dipivoxil combined with interferon α-2b in treatment of chronic hepatitis B patients

作　　者：钱林[1] 胡小宣[1] 刘洪娟[1] 

机构地区：[1]湖南省人民医院肝病内科,长沙410005

出　　处：《中国医师杂志》2016年第3期366-369,共4页Journal of Chinese Physician

基　　金：湖南省科技厅项目（2015SK2048）

摘　　要：目的 比较慢性乙肝患者应用阿德福韦酯联合国产重组人干扰素α-2b与单独应用阿德福韦酯或干扰素的抗病毒疗效.方法 选取本院2008年1月至2014年12月肝病门诊收治的乙型肝炎患者90例,按随机数字表法分为阿德福韦酯治疗组33例、干扰素治疗组28例、联合治疗组29例,观察三组患者的肝功能及乙肝病毒标志物的转换情况,并进行比较分析.结果 治疗48周,联合治疗组在HBeAg血清转换率、ALT复常率、HBV-DNA阴转率均显著好于单药治疗组,差异具有统计学意义（P＜0.05）.结论 应用阿德福韦酯联合国产重组人干扰素α-2b抗病毒,比单独用药治疗能够更有效的清除乙肝病毒,改善患者的临床症状与体征,具有确切的临床疗效.Objective To investigate clinical efficacy of adefovir dipivoxil （ADV） combined with interferon α-2b in treatment of chronic hepatitis B.Methods During Jan 2008 to Dec 2014,ninety patients with chronic hepatitis B were divided into adefovir dipivoxil group （33 cases）,interferon group （28 cases）,and adefovir dipivoxil combined with interferon α-2b group （29 cases）.Alanine aminotransferase （ALT） normalization rate,negative rate of HBV-DNA,and HBeAg/anti-HBe seroconversion rates were evaluated among three groups.Results After 48 weeks of treatment,HBeAg negative rate,HBV-DNA negative rate,and ALT normalization rate of combination group were significantly higher than that of interferons αt-2b group and adefovir dipivoxil group （P 〈 0.05）.Conclusions Adefovir dipivoxil combined with interferon α-2b treatment can inhibit the hepatitis B virus,increase the negative rate of HBV-DNA and HBeAg,and reduce liver cell damage.

关 键 词：膦酸类/投药和剂量 腺嘌呤/类似物和衍生物/投药和剂量 干扰素α-2b/类似物和衍生物/投药和剂量 肝炎 乙型 慢性/药物疗法 

分 类 号：R512.62[医药卫生—内科学]